A detailed history of Crestline Management, LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Crestline Management, LP holds 137,988 shares of CLDX stock, worth $3.14 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
137,988
Previous 85,351 61.67%
Holding current value
$3.14 Million
Previous $3.16 Million 48.42%
% of portfolio
0.25%
Previous 0.25%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$32.06 - $44.56 $1.69 Million - $2.35 Million
52,637 Added 61.67%
137,988 $4.69 Million
Q2 2024

Aug 13, 2024

BUY
$32.76 - $42.56 $526,191 - $683,598
16,062 Added 23.18%
85,351 $3.16 Million
Q1 2024

May 14, 2024

BUY
$35.22 - $51.88 $72,060 - $106,146
2,046 Added 3.04%
69,289 $2.91 Million
Q4 2023

Feb 12, 2024

BUY
$22.61 - $40.65 $93,447 - $168,006
4,133 Added 6.55%
67,243 $2.67 Million
Q3 2023

Nov 14, 2023

BUY
$25.45 - $37.46 $544,197 - $801,007
21,383 Added 51.24%
63,110 $1.74 Million
Q2 2023

Aug 14, 2023

BUY
$30.29 - $38.28 $347,274 - $438,880
11,465 Added 37.89%
41,727 $1.42 Million
Q1 2023

May 15, 2023

SELL
$34.78 - $47.43 $212,262 - $289,465
-6,103 Reduced 16.78%
30,262 $1.09 Million
Q4 2022

Feb 13, 2023

SELL
$27.78 - $45.38 $100,785 - $164,638
-3,628 Reduced 9.07%
36,365 $1.62 Million
Q3 2022

Nov 14, 2022

BUY
$22.7 - $37.57 $43,130 - $71,383
1,900 Added 4.99%
39,993 $1.12 Million
Q2 2022

Aug 12, 2022

BUY
$20.5 - $37.33 $122,959 - $223,905
5,998 Added 18.69%
38,093 $1.03 Million
Q1 2022

May 16, 2022

BUY
$27.64 - $39.32 $887,105 - $1.26 Million
32,095 New
32,095 $1.09 Million

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.06B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Crestline Management, LP Portfolio

Follow Crestline Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Crestline Management, LP with notifications on news.